Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC

BACKGROUND: Alectinib is approved for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring ALK rearrangements. Although generally well tolerated, alectinib can cause serious or life-threatening side effects. CASE PRESENTATION: Here, we report a case of a patient with NSCLC with an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Peng, Ling, Xiao, Kui, Cui, Jian, Ye, Xiang-Hua, Zhang, Yong-Chang, Mao, Li, Selvaggi, Giovanni, Yen, Jennifer, Stebbing, Justin
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2021
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8164872/
https://ncbi.nlm.nih.gov/pubmed/34079286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S310756
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados